MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes.
MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes.
复制标题
DOI:
10.1186/s12933-022-01602-9
复制
发表时间:
2022-08-27
影响因子:
9.3
通讯作者:
Peng, Tianqing
中科院分区:
文献类型:
--
作者:
Cao, Ting;Ni, Rui;Ding, Weimin;Ji, Xiaoyun;Li, Lan;Liao, Guangneng;Lu, Yanrong;Fan, Guo-Chang;Zhang, Zhuxu;Peng, Tianqing
Cardiomyocyte death contributes to cardiac pathology of diabetes. Studies have shown that the RIPK3/MLKL necroptosis signaling is activated in diabetic hearts. Deletion of RIPK3 was reported to attenuate myocardial injury and heart dysfunction in streptozocin (STZ)-induced diabetic mice, suggesting a potential role of necroptosis in diabetic cardiomyopathy. This study characterized cardiomyocyte necroptosis in diabetic hearts and investigated whether MLKL-mediated necroptosis is a target for cardiac protection in diabetes. Type 1 diabetes was induced in RIPK3 knockout, MLKL knockout and wild-type mice. Akita Type-1 diabetic mice were injected with shRNA for MLKL. Myocardial function was assessed by echocardiography. Immuno-histological analyses determined cardiomyocyte death and fibrosis in the heart. Cultured adult mouse cardiomyocytes were incubated with high glucose in the presence of various drugs. Cell death and phosphorylation of RIPK3 and MLKL were analysed. We showed that the levels of phosphorylated RIPK3 and MLKL were higher in high glucose-stimulated cardiomyocytes and hearts of STZ-induced type-1 diabetic mice, akita mice and type-1 diabetic monkeys when compared to non-diabetic controls. Inhibition of RIPK3 by its pharmacological inhibitor or gene deletion, or MLKL deletion prevented high glucose-induced MLKL phosphorylation and attenuated necroptosis in cardiomyocytes. In STZ-induced type-1 diabetic mice, cardiomyocyte necroptosis was present along with elevated cardiac troponin I in serum and MLKL oligomerization, and co-localized with phosphorylated MLKL. Deletion of RIPK3 or MLKL prevented MLKL phosphorylation and cardiac necroptosis, attenuated serum cardiac troponin I levels, reduced myocardial collagen deposition and improved myocardial function in STZ-injected mice. Additionally, shRNA-mediated down-regulation of MLKL reduced cardiomyocyte necroptosis in akita mice. Interestingly, incubation with anti-diabetic drugs (empagliflozin and metformin) prevented phosphorylation of RIPK3 and MLKL, and reduced cell death in high glucose-induced cardiomyocytes. We have provided evidence that cardiomyocyte necroptosis is present in diabetic hearts and that MLKL-mediated cardiomyocyte necroptosis contributes to diabetic cardiomyopathy. These findings highlight MLKL-mediated necroptosis as a target for cardiac protection in diabetes. The online version contains supplementary material available at 10.1186/s12933-022-01602-9.
登录
查看更多内容
影响因子:
3.4
作者:
Fang T;Cao R;Wang W;Ye H;Shen L;Li Z;Hu J;Gao Q
通讯作者:
Gao Q
影响因子:
5
作者:
Hsu, Hsiu-Ching;Chen, Ching-Yi;Chen, Ming-Fong
通讯作者:
Chen, Ming-Fong
影响因子:
7.7
作者:
Li J;Zhu H;Shen E;Wan L;Arnold JM;Peng T
通讯作者:
Peng T
DOI:
10.1007/978-1-4939-8754-2_8
发表时间:
2018-01-01
期刊:
PROGRAMMED NECROSIS: METHODS AND PROTOCOLS
影响因子:
--
作者:
Cai, Zhenyu;Liu, Zheng-Gang
通讯作者:
Liu, Zheng-Gang
影响因子:
8.8
作者:
Dondelinger, Yves;Declercq, Wim;Vandenabeele, Peter
通讯作者:
Vandenabeele, Peter